May 23, 2023
Eisai and Biogen said on May 22 that they have filed lecanemab in the UK (excluding Northern Ireland) for an indication of early Alzheimer’s disease (AD) with confirmed amyloid pathology in the brain. The UK Medicines and Healthcare products Regulatory...read more